DE602004029160D1 - - Google Patents

Info

Publication number
DE602004029160D1
DE602004029160D1 DE602004029160T DE602004029160T DE602004029160D1 DE 602004029160 D1 DE602004029160 D1 DE 602004029160D1 DE 602004029160 T DE602004029160 T DE 602004029160T DE 602004029160 T DE602004029160 T DE 602004029160T DE 602004029160 D1 DE602004029160 D1 DE 602004029160D1
Authority
DE
Germany
Prior art keywords
disorder
adenosine
receptor antagonist
phobia
agoraphobia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029160T
Other languages
German (de)
English (en)
Inventor
Hiroshi Kase
Naoki Seno
Shizuo Shiozaki
Minoru Kobayashi
Junya Kase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of DE602004029160D1 publication Critical patent/DE602004029160D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE602004029160T 2003-06-10 2004-06-10 Expired - Lifetime DE602004029160D1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US53279303P 2003-12-24 2003-12-24
PCT/JP2004/008486 WO2004108137A1 (en) 2003-06-10 2004-06-10 A method of treating an anxiety disorder

Publications (1)

Publication Number Publication Date
DE602004029160D1 true DE602004029160D1 (https=) 2010-10-28

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029160T Expired - Lifetime DE602004029160D1 (https=) 2003-06-10 2004-06-10

Country Status (15)

Country Link
US (2) US8202869B2 (https=)
EP (1) EP1631294B1 (https=)
JP (1) JP4778894B2 (https=)
KR (1) KR20060037252A (https=)
CN (1) CN1787821A (https=)
AT (1) ATE481101T1 (https=)
AU (1) AU2004244906A1 (https=)
BR (1) BRPI0411120A (https=)
CA (1) CA2528710C (https=)
CO (1) CO5640121A2 (https=)
DE (1) DE602004029160D1 (https=)
EA (1) EA200501924A1 (https=)
MX (1) MXPA05013148A (https=)
NO (1) NO20055907L (https=)
WO (1) WO2004108137A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
AU2008279169A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US8609162B2 (en) 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2051772T3 (es) * 1986-09-30 1994-07-01 Ciba Geigy Ag 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
ES2176204T3 (es) * 1992-07-08 2002-12-01 Kyowa Hakko Kogyo Kk Antidepresivos que contienen un derivado de xantina.
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
WO2000017201A1 (en) * 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
KR100687954B1 (ko) * 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
AU2002340405A1 (en) * 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Also Published As

Publication number Publication date
EP1631294A1 (en) 2006-03-08
CO5640121A2 (es) 2006-05-31
EA200501924A1 (ru) 2006-06-30
CA2528710A1 (en) 2004-12-16
JP2006527264A (ja) 2006-11-30
US20060281770A1 (en) 2006-12-14
BRPI0411120A (pt) 2006-07-18
CA2528710C (en) 2012-04-17
CN1787821A (zh) 2006-06-14
JP4778894B2 (ja) 2011-09-21
ATE481101T1 (de) 2010-10-15
US8592420B2 (en) 2013-11-26
EP1631294B1 (en) 2010-09-15
MXPA05013148A (es) 2006-03-17
WO2004108137A1 (en) 2004-12-16
AU2004244906A1 (en) 2004-12-16
NO20055907L (no) 2005-12-13
KR20060037252A (ko) 2006-05-03
US20120232089A1 (en) 2012-09-13
US8202869B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
DE602004029160D1 (https=)
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
MXPA04012614A (es) Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BRPI0412411A (pt) tetrahidro-1h-pirazol[3,4-c]piridinas substituìdas, composições que as contêm e utilização
MX373050B (es) Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojos.
IL189914A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
TW200637522A (en) Skin treatment articles and methods
WO2009043051A3 (en) Cd23 binding molecules and methods of use thereof
IL211085A0 (en) Perfusion solution
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
MY172641A (en) High concentration antibody and protein formulations
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
ATE541859T1 (de) Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
WO2009061924A3 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
WO2006072348A3 (de) Alkinyl-substituierte thiophene
SE0301654D0 (sv) Novel compounds
WO2007053796A3 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
UA93387C2 (ru) Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq